RecruitingNeuroblastoma
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
Eligible age
Up to 22 yrs
Accepts
All genders
Locations
19 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
A prospective open label, multicenter study to evaluate the feasibility and acute toxicity of using molecularly guided therapy in combination with standard therapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Subjects with Newly Diagnosed High-Risk Neuroblastoma.
Sponsor: Giselle Sholler
You may not qualify if…
- ✕ 1. Subjects who are 12-18 months of age with INSS Stage 4 and all stage 3 subjects with favorable biologic features (ie, nonamplified MYCN, favorable pathology, and DNA index \> 1) are not eligible.
- ✕ 2. Lactating females are not eligible unless they have agreed not to breastfeed their infants.
- ✕ 3. Subjects receiving any investigational drug concurrently.
- ✕ 4. Subjects with any other medical condition, including but not limited to malabsorption syndromes, mental illness or substance abuse, deemed by the Investigator to be likely to interfere with the interpretation of the results or which would interfere with a subject's ability to sign or the legal guardian's ability to sign the informed consent, and subject's ability to cooperate and participate in the study
Where it's recruiting
Source: ClinicalTrials.gov · NCT02559778 · last updated 2026-04-28